FDA approves Eli Lilly’s weight loss drug Zepbound for sleep apnea
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. Shelby Knowles | Bloomberg | Getty Images The Food and Drug Administration on Friday approved Eli Lilly‘s blockbuster weight loss drug Zepbound for treating patients with the most common sleep-related breathing disorder, expanding…